Generic Name: doravirine + tenofovir disoproxil fumarate + lamivudine

Pronunciation: del-STREE-go

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Single-Tablet Regimens

Company: Merck & Company

Approval Status: Approved

Generic Version Available: No

Experimental Code: MK-1439A


Drug Indication

The U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents lists Delstrigo as a recommended initial HIV treatment regimens in certain clinical situations. 


General Info

Delstrigo is single-tablet regimen for HIV containing the non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine and generic versions of two nucleoside/nucleotide reverse transcriptase inhibitors, tenofovir disoproxil fumarate (TDF) and lamivudine.

It was approved by the U.S. Food and Drug Administration in August 2018, for people starting HIV treatment for the first time. In September 2019, it was approved for people currently on treatment with an undetectable viral load who want to change to a new regimen.


Dosage

Adult Dose: One tablet once a day. Each tablet contains 100mg doravirine + 300mg tenofovir disoproxil fumarate + 300mg lamivudine.

For adults taking the antibiotic rifabutin, Delstrigo should be taken once a day, followed by one tablet of Pifeltro (darunavir) approximately 12 hours later.

Pediatric Dose: N/A

Dosing Info: This is a complete one-pill, once-daily drug regimen. Take with or without food.


Side Effects

Common side effects associated with Delstrigo inlcude dizziness, nausea, and abnormal dreams.

People living with both HIV and hepatitis B virus (HBV) should be carefully monitored if they stop taking Delstrigo.


Drug Interactions

For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Delstrigo or may require dose adjustments, consult the Delstrigo package insert: https://www.merck.com/product/usa/pi_circulars/d/delstrigo/delstrigo_pi.pdf


Other Info

Before taking this medication, tell your doctor if you have kidney disease or liver disease (including hepatitis B). In addition, tell your doctor if you are pregnant or planning to become pregnant; if you are breast feeding, and all your medical conditions, including all prescription and over-the-counter medications and supplements you are taking.


For More Info: https://www.merck.com/product/usa/pi_circulars/d/delstrigo/delstrigo_pi.pdf

Co-Pay Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs

Patient Assistance Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs

Last Reviewed: September 20, 0019